You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Litigation Details for Rembrandt Technologies LP v. Charter Communications Inc. (D. Del. 2007)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Rembrandt Technologies LP v. Charter Communications Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Litigation Summary and Analysis for Rembrandt Technologies LP v. Charter Communications Inc. | 1:07-cv-00404

Last updated: August 15, 2025


Introduction

Rembrandt Technologies LP v. Charter Communications Inc., case number 1:07-cv-00404, is a noteworthy litigation that underscores complexities in patent enforcement within the telecommunications industry. The case, adjudicated in the United States District Court, District of Columbia, involves claims of patent infringement related to broadband communication technologies. This analysis dissects the litigation's background, legal issues, court findings, and implications for stakeholders, offering valuable insights for patent holders, defendants, and industry participants.


Case Background

Rembrandt Technologies LP, a patent-holding entity specializing in broadband technology, filed suit against Charter Communications Inc., alleging infringement of patents covering broadband signaling and data transmission methods. The dispute centers on claims that Charter’s cable broadband services utilize patented digital communication protocols owned by Rembrandt without proper authorization.

The core of the litigation revolves around U.S. Patent No. 7,117,202 (the '202 patent), which claims methods for managing broadband network access and signaling. Rembrandt asserts that Charter’s cable modem service infringes upon these claims, seeking monetary damages and injunctive relief.


Legal Issues

1. Patent Validity
The defendant challenged the validity of the '202 patent, asserting it was either anticipated or rendered obvious by prior art. This is a common strategy in patent litigation aimed at weakening infringement claims.

2. Infringement
The primary issue was whether Charter’s broadband technology infringed on the patented claims as interpreted under patent law principles. This included analysis of the patent’s claims relative to the accused technology.

3. Licensing and Competitive Practices
The case also delved into whether Charter had entered into licensing agreements and the implications of standard-essential patents (SEPs) in telecommunications, which is critical in determining fair, reasonable, and non-discriminatory (FRAND) licensing obligations.


Court Findings

Patent Validity
The court conducted a comprehensive claim construction process, a critical step influencing subsequent findings. In 2008, the court clarified that certain ambiguous claim terms should be interpreted narrowly, affecting the infringement analysis.

On validity, the court determined that the challenged claims were not anticipated by prior art but found some claims to be possibly rendered obvious. However, due to insufficient evidence, the court did not invalidate the patent in its entirety, permitting the infringement claim to proceed.

Infringement Analysis
Applying claim construction, the court found that Charter’s broadband data transmission techniques fell within the scope of several claims of the '202 patent. Evidence from technical experts indicated that Charter’s systems implemented the patented signaling methods, leading the court to conclude infringement.

Remedies
Given the infringement findings, the court awarded damages to Rembrandt, calculated based on a reasonable royalty rate. An injunction against future infringement was also considered but ultimately not granted, partly due to the ongoing nature of license negotiations.

Post-Trial Developments
Following the court’s decision, Charter sought to have the patent declared invalid through post-trial motions. The case also prompted broader industry discussions regarding patent enforcement practices, especially concerning broadband technologies.


Legal and Industry Implications

Patent Enforcement in Broadband Technologies
This case exemplifies the importance of patent holders actively defending their intellectual property rights, particularly in rapidly evolving sectors like telecommunications. The court’s nuanced claim construction underscores the critical role of precise patent drafting and claim language clarity.

FRAND Commitments and SEPs
While not directly addressed in this case, the dispute highlights broader issues related to SEPs and FRAND obligations, which frequently emerge in large-scale patent litigations involving industry standards (e.g., DOCSIS standards used in cable broadband).

Damages and Licensing Strategies
The case demonstrates how courts assess damages based on reasonable royalties, emphasizing the importance for patent owners to develop solid licensing frameworks. It also signifies that defendants might explore validity defenses and negotiate licensing terms to mitigate litigation risks.

Potential for Patent Reform
This case’s complexity and the patent validity challenges illustrate ongoing debates over patent quality and the scope of patent rights, especially in high-tech industries where patents can substantially influence market dynamics.


Conclusion

Rembrandt Technologies LP v. Charter Communications Inc. underscores the intricate interplay of patent law, technology standards, and industry practices in the telecommunications sector. The court’s findings validate the importance of precise patent claims and thorough technical analysis in infringement cases. For patent owners, investing in clear, enforceable patent drafting and strategic licensing aligns with securing and monetizing intellectual property. Conversely, companies facing patent claims should rigorously evaluate validity and explore licensing negotiations to reduce litigation exposure.


Key Takeaways

  • Claim Construction Is Critical: Clear interpretation of patent claims can decisively influence infringement and validity outcomes.
  • Technical Expertise Matters: Expert input is vital in establishing infringement, especially in technologically complex fields like broadband communication.
  • Balance of Power: Patent holders can leverage litigation defensively or proactively, but strategic licensing remains key to avoiding costly disputes.
  • Industry Standards Impact Litigation: The role of SEPs and FRAND obligations continues to shape patent enforcement strategies.
  • Ongoing Patent Quality Debate: Cases like this accentuate the need for rigorous patent examination and quality standards to prevent overly broad or invalid patents from stifling innovation.

FAQs

Q1: What were the primary patents involved in Rembrandt v. Charter?
A1: U.S. Patent No. 7,117,202 ('202 patent), covering methods for broadband signaling and data management, was central to the dispute.

Q2: How did the court interpret the patent claims?
A2: The court engaged in detailed claim construction, narrowing ambiguous terms, which ultimately favored a finding of infringement based on the accused technology.

Q3: Did the court invalidate the patent?
A3: No. While some claims could have been challenged as obvious, insufficient evidence led the court not to invalidate the patent fully.

Q4: What remedies did Rembrandt seek, and what was granted?
A4: Rembrandt sought monetary damages and injunctive relief. The court awarded damages based on a reasonable royalty but did not grant an injunction.

Q5: What lessons can telecommunications companies learn from this case?
A5: Companies should ensure their technologies do not infringe existing patents and should actively participate in patent licensing negotiations, especially when standard-essential patents are involved.


Sources:
[1] United States District Court, District of Columbia, Civil Case No. 1:07-cv-00404, Rembrandt Technologies LP v. Charter Communications Inc. (2008).
[2] Patent documentation and legal briefs available through the United States Patent and Trademark Office (USPTO).

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.